We are live on !
Find out more
Kinnevik AB Portfolio holdings
AUM
$65.6M
Turnover
0%
1-Year Est. Return
25.95%
This Fund
S&P 500
This Quarter Est. Return
-3.56%
1 Year Est. Return
-25.95%
3 Year Est. Return
-51.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$65.6M
AUM Growth
-$2.42M
(-3.6%)
Cap. Flow
$0
Cap. Flow % of AUM
Cap. Flow %
0%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
–
Increased
–
Reduced
–
Closed
–
Avg Time Held
2.8
years
Top 10 Avg Time Held
2.8
years
Top 20 Avg Time Held
2.8
years
Top Buys
No buys this quarter
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Recursion Pharmaceuticals
RXRX
$2.52B
| $65.6M | 100% |
13,434,171
| – | – |
2022 Q4
11 quarters
|
|
Similar funds
KAM
EVP
A
Kinnevik AB's Q3 2025 Portfolio in Review
As of Q3 2025, Kinnevik AB held 1 position worth $65.6M, down 3.6% from $68M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q3 2025: portfolio turnover was 0%. Kinnevik AB opened no new positions and made no exits, leaving the 1-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Kinnevik AB's ten largest holdings make up 100% of its $65.6M portfolio in Q3 2025.
- Kinnevik AB opened 0 new positions and closed 0 in Q3 2025.
- Kinnevik AB's portfolio value fell 3.6% quarter-over-quarter to $65.6M.
Based on Kinnevik AB's 13F filing for Q3 2025, filed 4 Nov 2025.